Visit COVID-19 resources

[Skip to Content]

Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy – (Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy, Published online: 2018-12-03; | doi:10.1038/s41433-018-0286-x)

Dec 03
2018

Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy, Published online: 03 December 2018; doi:10.1038/s41433-018-0286-x Optical coherence tomography angiography characteristics in diabetic patients without clinical diabetic retinopathy

  • 3 December 2018

Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy – (Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy, Published online: 2018-11-30; | doi:10.1038/s41433-018-0297-7)

Nov 30
2018

Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital eye service follow-up for patients with screen-positive maculopathy, Published online: 30 November 2018; doi:10.1038/s41433-018-0297-7 Cost-effectiveness of digital surveillance clinics with optical coherence tomography versus hospital

  • 30 November 2018

Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both – (Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both, Published online: 2018-11-29; | doi:10.1038/s41433-018-0280-3)

Nov 29
2018

Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both Implications for pharmaceutical companies and clinicians from the <i>Bayer</i> v <i>NHS</i> judgement: an increasing budgetary focus for both, Published online: 29 November 2018; doi:10.1038/s41433-018-0280-3 Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an

  • 29 November 2018

Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease – (Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease, Published online: 2018-11-29; | doi:10.1038/s41433-018-0289-7)

Nov 29
2018

Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease Real-world experience at a Scottish university teaching hospital regarding the tolerability and persistence with topical Ciclosporin 0.1% (Ikervis) treatment in patients with dry eye disease, Published online: 29 November 2018;

  • 29 November 2018

Unique presentation of congenital cataract concurrent with microcornea, microphthalmia plus posterior capsule defect in monozygotic twins caused by a novel GJA8 mutation – (Unique presentation of congenital cataract concurrent with microcornea, microphthalmia plus posterior capsule defect in monozygotic twins caused by a novel GJA8 mutation, Published online: 2018-11-29; | doi:10.1038/s41433-018-0277-y)

Nov 29
2018

Unique presentation of congenital cataract concurrent with microcornea, microphthalmia plus posterior capsule defect in monozygotic twins caused by a novel GJA8 mutation Unique presentation of congenital cataract concurrent with microcornea, microphthalmia plus posterior capsule defect in monozygotic twins caused by a novel <i>GJA8</i> mutation, Published online: 29 November 2018; doi:10.1038/s41433-018-0277-y Unique presentation of congenital cataract

  • 29 November 2018